Skip to content

Effect of Agarwood (Aquilaria Sinensis) Inhalation Aromatherapy on Workplace Fatigue and Sleep Quality Among Hospital Employees: A Randomized Controlled Trial

A Randomized Controlled Trial Examining the Impact of Agarwood Aromatherapy Inhalation on Sleep Quality and Occupational Fatigue in Hospital Staff

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07188831
Enrollment
78
Registered
2025-09-23
Start date
2025-09-30
Completion date
2026-07-31
Last updated
2025-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fatigue, Occupational Stress or Workplace Stress, Sleep Quality

Brief summary

Hospital staff often experience workplace fatigue and poor sleep quality, which can harm their health, reduce job performance, and increase risks to patient safety. Aromatherapy is a simple, non-invasive complementary therapy that may help reduce fatigue and improve sleep. Agarwood (Aquilaria spp.) has calming and relaxing properties, but there is little clinical research on its effectiveness for hospital staff. This randomized, double-blind, controlled trial will evaluate whether agarwood aromatherapy inhalation can improve fatigue and sleep quality among hospital employees in Taiwan. About 78 participants will be recruited and randomly assigned to one of two groups: 1. Experimental group: Agarwood sachet containing agarwood wood chips and essential oil. 2. Control group: Placebo sachet containing almond oil. Participants will place the sachet about 60 cm from the nose during sleep for 7 nights. Data will be collected using questionnaires on workplace fatigue and sleep quality (Pittsburgh Sleep Quality Index, PSQI). The main questions this study aims to answer are: 1. Does agarwood aromatherapy reduce workplace fatigue in hospital staff? 2. Does agarwood aromatherapy improve sleep quality compared with placebo? Findings are expected to provide scientific evidence for using agarwood inhalation as a safe and convenient strategy to improve staff well-being and support a healthier hospital environment.

Interventions

OTHERAgarwood Aromatherapy Inhalation

The experimental group will receive agarwood essential oil sachets as the aromatherapy intervention, and participants will place the sachet 60 cm from the nose during sleep for one week.

Sponsors

Da-Yeh University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* ≥20 years old, hospital employee working ≥30 hrs/week, employed ≥3 months * Not using sedatives/hypnotics * Normal olfactory function (verified with coffee/vinegar smell test) * Clear consciousness, can read and understand Chinese, no major communication barriers * Not participating in other aromatherapy or relaxation intervention studies

Exclusion criteria

* Major psychiatric disorders (e.g., major depression, schizophrenia) * Malignancy under active radio/chemotherapy * CNS diseases (e.g., brain tumor) * History of asthma, fragrance allergy, pregnancy * Chronic rhinitis, nasal surgery, anosmia * Permanent night-shift workers (≥ midnight to 5am, as defined by ILO, 1995)

Design outcomes

Primary

MeasureTime frameDescription
Workplace FatigueBaseline and after 1-week interventionChange in fatigue levels measured by the Chinese version of the Copenhagen Burnout Inventory (21 items across four domains: personal, work-related, client-related, and overcommitment). Higher scores indicate greater fatigue.

Secondary

MeasureTime frameDescription
Sleep QualityBaseline and after 1-week interventionChange in sleep quality measured by the Pittsburgh Sleep Quality Index (PSQI, 19 items, 7 domains). Total scores range from 0 to 21, with higher scores indicating poorer sleep quality.

Contacts

Primary ContactYi-chen Wu, PhD
yichenwu@mail.dyu.edu.tw+886-4-8511888

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026